Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Endocr Connect ; 11(10)2022 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-36006853

RESUMEN

Objective: This study aimed to report on 15 Japanese patients with acrodysostosis and pseudohypoparathyroidism (PHP) and analyze them using the newly proposed classification of the EuroPHP network to determine whether this classification system is suitable for Japanese patients. Design: We divided the patients into three groups based on hormone resistance, the number of fingers with short metacarpals, the existence of cone-shaped epiphyses and gene defects. Methods: We carried out clinical, radiological and genetic evaluations of two patients in group A (iPPSD5), six patients in group B (iPPDS4) and seven patients in group C (iPPSD2). Results: Group A consisted of two siblings without hormone resistance who had the most severe bone and physical developmental delays. PDE4D gene defects were detected in both cases. Group B consisted of six patients who showed hormone resistance without hypocalcemia. Short metacarpal bones with corn-shaped epiphyses were observed in all patients. In two cases, PRKAR1A gene defects were detected; however, their clinical and radiological features were not identical. The facial dysmorphism and developmental delay were less severe and PRKAR1A gene defects were detected in case B-3. Severe facial dysmorphism and deformity of metacarpal bones were observed, but no gene defect was detected in case B-1. Group C consisted of seven patients with PHP1a, four of whom had maternally inherited heterozygous inactivating mutations in one of the GNAS genes. The clinical and radiological features of the patients in group C were not identical either. Conclusions: The newly proposed classification is suitable for Japanese patients; however, heterogeneities still existed within groups B and C.

3.
J Cardiol ; 53(1): 15-9, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19167633

RESUMEN

BACKGROUND: We compared the clinical utility of additional intravenous immune globulin (IVIG) therapy with the clinical utility of steroid pulse therapy in patients with IVIG-resistant Kawasaki disease. METHODS: We enrolled 164 patients with Kawasaki disease who were treated with a single dose of IVIG (2 g/kg) and aspirin (30 mg/kg per day). Twenty-seven of these patients (16%) were resistant to the initial IVIG treatment. We compared the effectiveness of treatment strategies for the initial IVIG-resistant 27 patients, 14 of these patients were treated with additional IVIG therapy, and the other 13 patients were treated with steroid pulse therapy (methylprednisolone 30 mg/kg per day for 3 days). RESULTS: Three patients in the group receiving additional IVIG treatment had coronary artery aneurysms (21.4%), no patients had coronary artery aneurysm in the steroid pulse therapy group; the difference in the incidence of coronary artery aneurysm was not statistically significant. The duration of high fever after additional treatment in the steroid pulse therapy group (1 ± 1.3 days) was significantly shorter than that in the additional IVIG treatment group (3 ± 2.4 days; P < 0.05). The medical costs were significantly lower in the steroid pulse therapy group than in the additional IVIG treatment group. CONCLUSION: Steroid pulse therapy was useful to reduce the fever duration and medical costs for patients with Kawasaki disease. Steroid pulse therapy and additional IVIG treatment were not significantly different in terms of preventing the development of coronary artery aneurysm.


Asunto(s)
Inmunoglobulinas Intravenosas/administración & dosificación , Síndrome Mucocutáneo Linfonodular/tratamiento farmacológico , Esteroides/administración & dosificación , Niño , Preescolar , Aneurisma Coronario/complicaciones , Resistencia a Medicamentos , Femenino , Fiebre/tratamiento farmacológico , Humanos , Lactante , Masculino , Metilprednisolona/administración & dosificación , Síndrome Mucocutáneo Linfonodular/economía , Quimioterapia por Pulso , Vasculitis/complicaciones
4.
Pediatr Int ; 50(3): 269-75, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18533934

RESUMEN

BACKGROUND: The aim of the present paper was to investigate 20 pediatric patients with cerebral palsy and secondary osteoporosis and consider the efficacy, influence and index of treatment. METHODS: A total of 10 boys and 10 girls, age 1-16 years (mean 7.6 years) with secondary osteoporosis and cerebral palsy treated for 6 months, were studied. Bone mineral density (BMD) was measured. The bone turnover markers were measured just before and 4 months after treatment or at the time of early discontinuation of treatment. The treatment was classified into two groups: vitamin D (alfacarcidol) only; and with bisphosphonate (risedronate). RESULTS: Monotherapy with alfacarcidol was effective for secondary osteoporosis in children, but when used in combination with risedronate it was even more effective in improving BMD. In the two groups, bone-specific alkaline phosphate (BAP) decreased from pretreatment to post-treatment assessment in all but one case, but there was no significant correlation in the difference in DeltaBAP with DeltaBMD. DeltaBAP assumed changes in BAP in treatment either before or after, and DeltaBMD also assumed changes in BMD. N-telopeptides of type I collagen (NTX)/Cr decreased in all cases. The correlation of DeltaNTX/Cr with DeltaBMD was not significant. The therapy and its efficacy did not correlate to the patients' age, sex, medicine regimen or enteral nutrition. CONCLUSIONS: Risedronate therapy is effective for patients presenting with secondary osteoporosis with cerebral palsy. Moreover, it is desirable to treat patients more aggressively from the early stage because risedronate is not affected by the patients' other factors.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Conservadores de la Densidad Ósea/uso terapéutico , Parálisis Cerebral/complicaciones , Ácido Etidrónico/análogos & derivados , Hidroxicolecalciferoles/uso terapéutico , Osteoporosis/etiología , Absorciometría de Fotón , Adolescente , Fosfatasa Alcalina/metabolismo , Benzodiazepinas/uso terapéutico , Biomarcadores/metabolismo , Densidad Ósea , Parálisis Cerebral/tratamiento farmacológico , Niño , Preescolar , Clobazam , Colágeno Tipo I/metabolismo , Método Doble Ciego , Quimioterapia Combinada , Ácido Etidrónico/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Lactante , Isoxazoles/uso terapéutico , Vértebras Lumbares/diagnóstico por imagen , Masculino , Osteoporosis/tratamiento farmacológico , Osteoporosis/metabolismo , Péptidos/metabolismo , Estudios Retrospectivos , Ácido Risedrónico , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Zonisamida
6.
Endocr J ; 52(5): 505-10, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16284425

RESUMEN

Studies on thyrotropin receptor autoantibodies (TRAb) by measurement of both thyroid-stimulating antibodies (TSAb) and thyrotropin-binding inhibitory immunoglobulins (TBII) in serum from children with Graves' disease are limited in number of studies. The aim of this study was to investigate the levels of serum TSAb and TBII in children with Graves' disease, and to evaluate the clinical significance of these antibodies. We measured the serum TSAb and TBII at diagnosis and during management in 65 children with Graves' disease. Patients were divided into four groups according to their metabolic state: those with untreated active Graves' disease, those receiving treatment with antithyroid drugs, those in remission, and those in relapse. At diagnosis, both TSAb and TBII assays had high sensitivities and high specificities. In follow-up, the levels of both TSAb and TBII paralleled the course of the disease. There was a strong positive correlation between TSAb and TBII. TBII levels were significantly higher in the patients with ophthalmopathy than those without ophthalmopathy in untreated Graves' children. It was concluded that TSAb and TBII measurements are valuable in the diagnosis and management of children with Graves' disease.


Asunto(s)
Autoanticuerpos/análisis , Enfermedad de Graves/inmunología , Inmunoglobulinas Estimulantes de la Tiroides/sangre , Receptores de Tirotropina/inmunología , Adolescente , Antitiroideos/uso terapéutico , Autoanticuerpos/sangre , Niño , Femenino , Enfermedad de Graves/tratamiento farmacológico , Oftalmopatía de Graves/sangre , Oftalmopatía de Graves/inmunología , Humanos , Masculino , Receptores de Tirotropina/sangre , Recurrencia , Inducción de Remisión , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA